It is notable that ERNA recording obtained by cutting the distal end of the renal nerve to eliminate the afferent signal, demonstrated that response of increase in ERNA to GLP-1 is significantly diminished compared to that in total RSNA with intact renal nerves
Tirzepatide is an established, FDA-approved treatment with real-world outcomes, while Retatrutide remains investigational
Clinical trials of semaglutide (another GLP-1 agonist) showed a temporary increase in diabetic retinopathy complications, particularly in patients with pre-existing retinopathy who experienced rapid glycemic improvement
For example, a recent meta-analysis of two randomized controlled trials showed that SGLT2i significantly reduced N-terminal B-type ANP (NT-proBNP) levels compared with placebo [57, 58], although Ueda et al
This proactive approach aims not only to address current concerns but also to prevent future legal challenges by refining their product offerings